Autoantibody associated with SLE or Sjögren’s syndrome.
Autoantibody associated with SLE or Sjögren’s syndrome.
specific for lupus erythematosus (LE)
an extractable nuclear antigen (ENA) associated MCTD
Biomarker for atherosclerotic diseases
The number of small, dense LDL particles in your blood.
found almost exclusively in people with lupus
Smith/RNP (ENA) antibodies, predominantly of the IgG class, are a significant marker in the diagnostic landscape of autoimmune diseases, particularly systemic lupus erythematosus (SLE) and mixed connective tissue disease (MCTD). These antibodies target specific proteins found in the cell nucleus, making them a crucial component in the array of antinuclear antibodies (ANAs) often tested for in autoimmune diagnostics. In the context of SLE, the presence of Smith/RNP antibodies is relatively rare but highly specific. This means that while not all SLE patients have these antibodies, those who do are very likely to have SLE. This specificity makes Smith/RNP antibodies an invaluable tool in distinguishing SLE from other autoimmune disorders, which can often present with similar symptoms. On the other hand, in MCTD, these antibodies play a more central role. MCTD is characterized by symptoms that overlap with several other connective tissue diseases, including SLE, scleroderma, and polymyositis. The presence of high levels of Smith/RNP antibodies is a key factor in diagnosing MCTD, as it helps to delineate this condition from its counterparts. Testing for Smith/RNP antibodies is typically done through blood tests, where IgG antibodies are detected using techniques such as enzyme-linked immunosorbent assay (ELISA) or immunofluorescence. A positive test result for these antibodies, especially when correlated with clinical symptoms, can be a decisive factor in the diagnosis and management of autoimmune disorders. Understanding the role of Smith/RNP (ENA) antibodies, IgG in autoimmune diseases is crucial for both patients and healthcare providers. It not only aids in accurate diagnosis but also helps in monitoring disease progression and response to therapy. For those suspecting or managing an autoimmune condition, discussing Smith/RNP antibody testing with a healthcare professional can be an essential step in the journey towards better health management.
Smooth Muscle Antibodies (SMA), identified through the Immunofluorescence Assay (IFA), are pivotal in diagnosing autoimmune liver diseases, particularly Autoimmune Hepatitis (AIH). SMA-IFA testing detects antibodies targeting actin, a protein in smooth muscle cells, often found in patients with AIH. This test is crucial for differentiating AIH from other liver conditions like viral hepatitis, alcoholic liver disease, and non-alcoholic fatty liver disease. Positive SMA-IFA results, especially when combined with clinical findings and other laboratory tests, can significantly aid in confirming AIH. Early and accurate detection through SMA-IFA is essential for timely and effective treatment, reducing the risk of liver cirrhosis and liver failure. In the field of personalized healthcare, Smooth Muscle Abs, IFA testing is a key diagnostic tool, enhancing patient care through tailored treatment strategies for autoimmune liver diseases.
Autoimmune liver antibody
Sodium (Na+) and potassium (K+) are electrolytes that affect most metabolic functions. They serve to maintain osmotic pressure and hydration of various body fluid compartments, body pH and regulation of heart and muscle functions. Electrolytes are also involved in oxidation-reduction reactions and participate in essential enzymatic reactions. Electrolytes can be affected by state of hydration. Hemolysis can result in falsely elevated K+.